USPTO 2015–2025 USPTO PatentsView US Corporation

Forever Young International, Inc.

USPTO PatentsView assignee record - 18 granted patents across 20 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Forever ranks #16,023 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 20 technology areas.

#16,023
of 49,997 US assignees by volume
Top 43%
by Innovation Score (37.5/100)
13.7
avg claims per patent
-80%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16023 · US Corporation #16,023 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 18 grants
  • MID-PACK #16,023/49,997
  • PHOTO-FINISH FEI EFA
  • CPC-FOCUS A61F · 20 areas
  • INNOV-THIN 37.5/100
  • CLAIMS-RICH 13.7 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -80% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: FEI EFA, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Forever

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Forever's Innovation Score is 37.5/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Forever's grants concentrate

Forever Young International, Inc. is a focused PatentsView assignee: 20 CPC subclasses with 55.6% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2017 (4 grants) versus a trough of 1 in 2020. By volume, Forever sits between FEI EFA, Inc. and Freiberger Compound Materials GMBH.

Forever's three-year grant acceleration

Forever Young International, Inc. shows 2 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Forever's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Forever holds 18 patents at rank #16,014, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Forever

By rank, the assignees closest to #16,014 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Forever's primary technology class.

Forever's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 20152016201720182019202020232024 1
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Forever Young International, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 2 11.1%
2016 3 16.7%
2017 4 22.2%
2018 3 16.7%
2019 3 16.7%
2020 1 5.6%
2023 1 5.6%
2024 1 5.6%

Which technologies does Forever Young International, Inc. patent most?

Top 15 of 20 technology areas

Where it ranks

Overall rank by patents

#16,023

of 49,997 tracked assignees

Innovation Score

37.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Forever Young International, Inc.'s patent record in context - here's where to go next.

  • Forever Young International, Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 55.6% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #16,023 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Forever Young International, Inc. against FEI EFA, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 37.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.